{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:09:06Z","timestamp":1788923346800,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11684-026-1243-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:11:01Z","timestamp":1782954661000},"page":"546-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological complete response in a POLE-mutated non-small cell lung cancer patient treated with perioperative chemoimmunotherapy: a case report and review of the literature"],"prefix":"10.1007","volume":"20","author":[{"given":"Luigi","family":"Liguori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Santaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pagliara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Polcaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ventin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina R.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"1","key":"1243_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1): 7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"1243_CR2","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Aup\u00e9rin","year":"2010","unstructured":"Aup\u00e9rin A, Le P\u00e9choux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non\u2013small-cell lung cancer. J Clin Oncol 2010; 28(13): 2181\u20132190","journal-title":"J Clin Oncol"},{"issue":"9928","key":"1243_CR3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014; 383(9928): 1561\u20131571","journal-title":"Lancet"},{"key":"1243_CR4","doi-asserted-by":"publisher","first-page":"1611713","DOI":"10.3389\/pore.2024.1611713","volume":"30","author":"A Lieber","year":"2024","unstructured":"Lieber A, Makai A, Orosz Z, Kardos T, Isaac SJ, Tornyi I, Bittner N. The role of immunotherapy in early-stage and metastatic NSCLC. Pathol Oncol Res 2024; 30: 1611713","journal-title":"Pathol Oncol Res"},{"issue":"20","key":"1243_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, \u00d6zg\u00fcro\u01e7lu M. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20): 1919\u20131929","journal-title":"N Engl J Med"},{"issue":"4","key":"1243_CR6","doi-asserted-by":"publisher","first-page":"e246837","DOI":"10.1001\/jamanetworkopen.2024.6837","volume":"7","author":"GL Banna","year":"2024","unstructured":"Banna GL, Hassan MA, Signori A, Giunta EF, Maniam A, Anpalakhan S, Acharige S, Ghose A, Addeo A. Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Netw Open 2024; 7(4): e246837","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1243_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/curroncol32020110","volume":"32","author":"F de Marinis","year":"2025","unstructured":"de Marinis F, Ardizzoni A, Attili I, Bonanno L, Bria E, Cortinovis DL, Margaritora S, Mazzoni F, Mercadante E, Morabito A, Petrella F, Rea F, Salvi R, Solli P, Spaggiari L, Voltolini L, Gridelli C. Perioperative chemo-immunotherapy in non-oncogene-addicted resectable non-small cell lung cancer (NSCLC): Italian expert panel meeting. Curr Oncol 2025; 32(2): 110","journal-title":"Curr Oncol"},{"issue":"3","key":"1243_CR8","doi-asserted-by":"publisher","first-page":"pkae021","DOI":"10.1093\/jncics\/pkae021","volume":"8","author":"NA Waser","year":"2024","unstructured":"Waser NA, Quintana M, Schweikert B, Chaft JE, Berry L, Adam A, Vo L, Penrod JR, Fiore J, Berry DA, Goring S. Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis. JNCI Cancer Spectr 2024; 8(3): pkae021","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"1243_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","volume":"17","author":"M Mino-Kenudson","year":"2022","unstructured":"Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 2022; 17(12): 1335\u20131354","journal-title":"J Thorac Oncol"},{"key":"1243_CR10","doi-asserted-by":"publisher","first-page":"104554","DOI":"10.1016\/j.critrevonc.2024.104554","volume":"205","author":"L Liguori","year":"2025","unstructured":"Liguori L, Salomone F, Viggiano A, Sabbatino F, Pepe S, Formisano L, Bianco R, Servetto A. KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies. Crit Rev Oncol Hematol 2025; 205: 104554","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1243_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, Kato T, Majem M, Groh\u00e9 C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023; 389(2): 137\u2013147","journal-title":"N Engl J Med"},{"issue":"14","key":"1243_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","volume":"390","author":"YL Wu","year":"2024","unstructured":"Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024; 390(14): 1265\u20131276","journal-title":"N Engl J Med"},{"issue":"7","key":"1243_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JCH, Cobo M, \u00d6zg\u00fcro\u01e7lu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Huang X, Grainger E, Ghiorghiu D, van der Gronde T, Ramalingam SS. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024; 391(7): 585\u2013597","journal-title":"N Engl J Med"},{"issue":"6","key":"1243_CR14","doi-asserted-by":"publisher","first-page":"e2100267","DOI":"10.1200\/PO.21.00267","volume":"6","author":"B Garmezy","year":"2022","unstructured":"Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pili\u00e9 PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers. JCO Precis Oncol 2022; 6(6): e2100267","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1243_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/iub.1276","volume":"66","author":"EE Henninger","year":"2014","unstructured":"Henninger EE, Pursell ZF. DNA polymerase \u03b5 and its roles in genome stability. IUBMB Life 2014; 66(5): 339\u2013351","journal-title":"IUBMB Life"},{"issue":"11","key":"1243_CR16","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/cancers11111798","volume":"11","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 2019; 11(11): 1798","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1243_CR17","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3390\/cancers16071302","volume":"16","author":"S Verma","year":"2024","unstructured":"Verma S, Breadner D, Mittal A, Palma DA, Nayak R, Raphael J, Vincent M. An updated review of management of resectable stage III NSCLC in the era of neoadjuvant immunotherapy. Cancers (Basel) 2024; 16(7): 1302","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1243_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, L\u00f3pez Vivanco G, Camps C, L\u00f3pez-Castro R, Mor\u00e1n T, Barneto I, Rodr\u00edguez-Abreu D, Serna-Blasco R, Ben\u00edtez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Mart\u00edn-L\u00f3pez J, Cruz-Berm\u00fadez A, Massuti B, Romero A. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 2023; 389(6): 504\u2013513","journal-title":"N Engl J Med"},{"issue":"21","key":"1243_CR19","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022; 386(21): 1973\u20131985","journal-title":"N Engl J Med"},{"issue":"10","key":"1243_CR20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, Liu H, Gu Z, Huang L, Lu Q, Wang X, Sun J, Yang E, Wang T, Zhong D, Wang J, Zhao Z, Liu Z, Wang C, Wang X, Lei G, Yan X, Jiang T. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol 2023; 9(10): 1348\u20131355","journal-title":"JAMA Oncol"},{"issue":"4","key":"1243_CR21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/cancers13040804","volume":"13","author":"D K\u00f6nig","year":"2021","unstructured":"K\u00f6nig D, Savic Prince S, Rothschild SI. Targeted therapy in advanced and metastatic non-small cell lung cancer. an update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) 2021; 13(4): 804","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1243_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","volume":"45","author":"C Palles","year":"2013","unstructured":"Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, Barclay E, Gorman M, Martin L, Kovac MB, Humphray S, Lucassen A, Holmes CC, Bentley D, Donnelly P, Taylor J, Petridis C, Roylance R, Sawyer EJ, Kerr DJ, Clark S, Grimes J, Kearsey SE, Thomas HJW, McVean G, Houlston RS, Tomlinson I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45(2): 136\u2013144","journal-title":"Nat Genet"},{"issue":"11","key":"1243_CR23","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1101\/gr.174789.114","volume":"24","author":"E Shinbrot","year":"2014","unstructured":"Shinbrot E, Henninger EE, Weinhold N, Covington KR, G\u00f6ksenin AY, Schultz N, Chao H, Doddapaneni H, Muzny DM, Gibbs RA, Sander C, Pursell ZF, Wheeler DA. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 2014; 24(11): 1740\u20131750","journal-title":"Genome Res"},{"issue":"23","key":"1243_CR24","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/1759-7714.15012","volume":"14","author":"S Zheng","year":"2023","unstructured":"Zheng S, Cao Y, Randall J, Yu H, Thomas TO. Integrating POLE\/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer. Thorac Cancer 2023; 14(23): 2269\u20132274","journal-title":"Thorac Cancer"},{"issue":"1","key":"1243_CR25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","volume":"41","author":"X Ma","year":"2022","unstructured":"Ma X, Dong L, Liu X, Ou K, Yang L. POLE\/POLD1 mutation and tumor immunotherapy. J Exp Clin Cancer Res 2022; 41(1): 216","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1243_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-018-0832-y","volume":"17","author":"L Liu","year":"2018","unstructured":"Liu L, Ruiz J, O\u2019Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 2018; 17(1): 81","journal-title":"Mol Cancer"},{"key":"1243_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2018.02.004","volume":"118","author":"Z Song","year":"2018","unstructured":"Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. Lung Cancer 2018; 118: 57\u201361","journal-title":"Lung Cancer"},{"key":"1243_CR28","doi-asserted-by":"publisher","first-page":"817265","DOI":"10.3389\/fphar.2022.817265","volume":"13","author":"Y Fu","year":"2022","unstructured":"Fu Y, Zheng Y, Wang PP, Chen YY, Ding ZY. Immunotherapy for a POLE mutation advanced non-small-cell lung cancer patient. Front Pharmacol 2022; 13: 817265","journal-title":"Front Pharmacol"},{"issue":"6","key":"1243_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","volume":"12","author":"B Rousseau","year":"2022","unstructured":"Rousseau B, Bieche I, Pasmant E, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Svrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la Fouchardiere C, Flechon A, Rolland F, Hiret S, Saada-Bouzid E, Bouche O, Andre T, Pannier D, El Hajbi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaouti A, Diaz LA Jr, Saintigny P, Chevret S, Marabelle A. PD-1 blockade in solid tumors with defects in polymerase epsilon. Cancer Discov 2022; 12(6): 1435\u20131448","journal-title":"Cancer Discov"},{"issue":"10","key":"1243_CR30","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol 2019; 5(10): 1504\u20131506","journal-title":"JAMA Oncol"},{"issue":"3","key":"1243_CR31","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.cllc.2025.01.005","volume":"26","author":"MS Lara","year":"2025","unstructured":"Lara MS, Riess JW, Kaleka G, Borowsky A, McPherson JD, Godoy LA, Grego L, Lara PN Jr, Mitsiades N. POLE mutation associated with microsatellite instability and high tumor mutational burden confers exquisite sensitivity to immune checkpoint inhibitor therapy in non-small cell lung cancer: a case report and genomic database analysis. Clin Lung Cancer 2025; 26(3): e207\u2013e213","journal-title":"Clin Lung Cancer"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1243-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:37Z","timestamp":1788922177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1243-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1243-x","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Luigi Liguori, Rosario De Feo, Lucia Santaniello, Brigida Miranda, Valentina Pagliara, Giovanna Polcaro, Alessandro Caputo, Giulia Cattaneo, Marco Ventin, Alberto Servetto, Cristina R Ferrone, Stefano Pepe, and Francesco Sabbatino declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"Written informed consent to publish this paper has been obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}